Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D87PWZ
|
|||
| Drug Name |
IPH5201
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ectonucleoside triphosphate diphosphohydrolase 1 (CD39) | Target Info | Inhibitor | [1] |
| BioCyc | UTP and CTP dephosphorylation II | |||
| KEGG Pathway | Purine metabolism | |||
| Pyrimidine metabolism | ||||
| Epstein-Barr virus infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04261075) IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.